Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences T (JAGLX)

63.70
+0.95
+(1.51%)
At close: 8:04:20 PM EDT

Top 10 Holdings (41.77% of Total Assets)

SymbolCompany% Assets
Eli Lilly and Company 9.42%
UnitedHealth Group Incorporated 6.89%
AstraZeneca PLC 4.02%
Johnson & Johnson 3.60%
Boston Scientific Corporation 3.14%
Abbott Laboratories 3.10%
Sanofi 3.06%
Amgen Inc. 2.90%
AbbVie Inc. 2.83%
Vertex Pharmaceuticals Incorporated 2.82%

Sector Weightings

SectorJAGLX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 0.27%
Stocks 98.85%
Bonds 0.00%
Others 0.61%
Preferred 0.24%
Convertible 0.04%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JAGLX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.21 5.28
Price/Sales 0.45 2.06
Price/Cashflow 0.05 17.54
Median Market Cap 80,210.71 34,862.81
3 Year Earnings Growth 3.69 32.48

Bond Holdings

Performance & Risk

YTD Return -7.00%
5y Average Return 6.23%
Rank in Category (ytd) 33
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.68
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 4.66B
YTD Return 0.67%
Yield 0.21%
Morningstar Rating
Inception Date Jul 06, 2009

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers